SCHEMBL834357

SCHEMBL834357

O=[C]C(F)(F)C(F)(F)C(F)F

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.31
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6657771 0.82 KDM4E (0.38) KDM4ETSHRTDP1
SCHEMBL7780906 0.78 KDM4E (0.35) KDM4ETSHRTDP1
SCHEMBL7780897 0.78 KDM4E (0.35) KDM4ETSHRTDP1
SCHEMBL465571 0.78 KDM4E (0.35) KDM4ETSHRTDP1
SCHEMBL7567244 0.78 KDM4E (0.35) KDM4ETSHRTDP1
SCHEMBL6131428 0.77
SCHEMBL2201803 0.71
Carbon Dioxide SCHEMBL9245906 0.71 KDM4E (0.32) KDM4ETSHRTDP1
SCHEMBL465092 0.71
SCHEMBL7751964 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1988006732-A1 TAGGED BINDING REAGENTS AND METHODS FOR DETECTING TARGET ANALYTES ALLIED CORPORATION (US) 1988-09-07 WO claimed
US-8497397-B2 Substituted acrylamide derivative and pharmaceutical composition comprising the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-30 US disclosed
EP-1880720-B1 SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAIICHI SANKYO CO LTD (JP) 2013-02-13 EP disclosed
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-20120220593-A1 Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-08-30 US disclosed
US-8143446-B2 Substituted acrylamide derivative and pharmaceutical composition comprising the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-27 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
US-20090118199-A1 SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAIICHI SANKYO COMPANY , LIMITED (JP) 2009-05-07 US disclosed
EP-1908466-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-04-09 EP disclosed
EP-1880720-A1 SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-01-23 EP disclosed
US-4623617-A MAGENTA COUPLER AND S TABILIZER KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1986-11-18 US disclosed
EP-0201033-A2 A method for processing silver halide color photographic materials KONICA CORPORATION (JP) 1986-11-12 EP disclosed
EP-0200206-A2 Silver halide photographic light-sensitive material KONICA CORPORATION (JP) 1986-11-05 EP disclosed
EP-0199351-A2 Silver halide photographic material KONICA CORPORATION (JP) 1986-10-29 EP disclosed
EP-0199604-A2 Processing method for light-sensitive silver halide color photographic material KONICA CORPORATION (JP) 1986-10-29 EP disclosed
EP-0187521-A2 Light-sensitive silver halide photographic material KONICA CORPORATION (JP) 1986-07-16 EP disclosed
EP-0185506-A2 Light-sensitive silver halide photographic material KONICA CORPORATION (JP) 1986-06-25 EP disclosed
EP-0182486-A1 Silver halide color photographic material KONICA CORPORATION (JP) 1986-05-28 EP disclosed
EP-0178794-A1 Silver halide color photographic material KONICA CORPORATION (JP) 1986-04-23 EP disclosed
EP-0178165-A1 Silver halide color photographic material KONICA CORPORATION (JP) 1986-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME PTMS, C1S, ACP3 KDM4E 551/4885TSHR 1603/4885TDP1 3856/4885
US-20090118199-A1 SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME ACR, NAT1, C1S KDM4E 4414/4885TSHR 2046/4885TDP1 1470/4885
US-20120220593-A1 Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same ACR, NAT1, C1S KDM4E 4414/4885TSHR 2046/4885TDP1 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.